Paranasal sinus cancer

Paolo Bossi, Davide Farina, Gemma Gatta, Davide Lombardi, Piero Nicolai, Ester Orlandi

Research output: Contribution to journalArticle

Abstract

Paranasal sinus cancers are rare diseases, accounting for about 5% of all head and neck malignancies. The variety of histological types and the overlapping pathological features with other entities constitute difficulties in pathologic interpretation, often requiring a skilled interpretation or a second opinion. Treatment of locally advanced disease relies on surgery and radiation therapy for operable disease, with a possible role for systemic treatment in selected histologies within a multimodal approach; unresectable paranasal sinus cancers are generally treated with a combination of radiotherapy and chemotherapy. The employment of high conformal radiation techniques, such as Intensity Modulated Radiation Therapy orcharged particle therapy, proton or carbon ion therapy may improve outcome and reduce late effects. Surgical treatment has evolved due to the progressive application of transnasal endoscopic techniques for naso-ethmoidal malignancies and due to innovative reconstructive techniques after resection of cancers of the maxillary sinus. Because of the rarity and complexity of this disease, multicenter trials represent an urgent need to improve prognosis and to reduce treatment-related effects.

Original languageEnglish
Pages (from-to)45-61
Number of pages17
JournalCritical Reviews in Oncology/Hematology
Volume98
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Paranasal Sinus Neoplasms
Radiotherapy
Maxillary Sinus Neoplasms
Heavy Ion Radiotherapy
Proton Therapy
Therapeutics
Rare Diseases
Combination Drug Therapy
Multicenter Studies
Neoplasms
Histology
Neck
Referral and Consultation
Head
Radiation

Keywords

  • Chemotherapy
  • Environmental causes
  • Follow up
  • Late sequelae
  • Paranasal sinus cancers
  • Prognostic factors
  • Radiotherapy
  • Staging-molecular alterations
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Paranasal sinus cancer. / Bossi, Paolo; Farina, Davide; Gatta, Gemma; Lombardi, Davide; Nicolai, Piero; Orlandi, Ester.

In: Critical Reviews in Oncology/Hematology, Vol. 98, 01.02.2016, p. 45-61.

Research output: Contribution to journalArticle

Bossi, Paolo ; Farina, Davide ; Gatta, Gemma ; Lombardi, Davide ; Nicolai, Piero ; Orlandi, Ester. / Paranasal sinus cancer. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 98. pp. 45-61.
@article{576edf5326a544cea994b0050250591c,
title = "Paranasal sinus cancer",
abstract = "Paranasal sinus cancers are rare diseases, accounting for about 5{\%} of all head and neck malignancies. The variety of histological types and the overlapping pathological features with other entities constitute difficulties in pathologic interpretation, often requiring a skilled interpretation or a second opinion. Treatment of locally advanced disease relies on surgery and radiation therapy for operable disease, with a possible role for systemic treatment in selected histologies within a multimodal approach; unresectable paranasal sinus cancers are generally treated with a combination of radiotherapy and chemotherapy. The employment of high conformal radiation techniques, such as Intensity Modulated Radiation Therapy orcharged particle therapy, proton or carbon ion therapy may improve outcome and reduce late effects. Surgical treatment has evolved due to the progressive application of transnasal endoscopic techniques for naso-ethmoidal malignancies and due to innovative reconstructive techniques after resection of cancers of the maxillary sinus. Because of the rarity and complexity of this disease, multicenter trials represent an urgent need to improve prognosis and to reduce treatment-related effects.",
keywords = "Chemotherapy, Environmental causes, Follow up, Late sequelae, Paranasal sinus cancers, Prognostic factors, Radiotherapy, Staging-molecular alterations, Surgery",
author = "Paolo Bossi and Davide Farina and Gemma Gatta and Davide Lombardi and Piero Nicolai and Ester Orlandi",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.critrevonc.2015.09.009",
language = "English",
volume = "98",
pages = "45--61",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Paranasal sinus cancer

AU - Bossi, Paolo

AU - Farina, Davide

AU - Gatta, Gemma

AU - Lombardi, Davide

AU - Nicolai, Piero

AU - Orlandi, Ester

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Paranasal sinus cancers are rare diseases, accounting for about 5% of all head and neck malignancies. The variety of histological types and the overlapping pathological features with other entities constitute difficulties in pathologic interpretation, often requiring a skilled interpretation or a second opinion. Treatment of locally advanced disease relies on surgery and radiation therapy for operable disease, with a possible role for systemic treatment in selected histologies within a multimodal approach; unresectable paranasal sinus cancers are generally treated with a combination of radiotherapy and chemotherapy. The employment of high conformal radiation techniques, such as Intensity Modulated Radiation Therapy orcharged particle therapy, proton or carbon ion therapy may improve outcome and reduce late effects. Surgical treatment has evolved due to the progressive application of transnasal endoscopic techniques for naso-ethmoidal malignancies and due to innovative reconstructive techniques after resection of cancers of the maxillary sinus. Because of the rarity and complexity of this disease, multicenter trials represent an urgent need to improve prognosis and to reduce treatment-related effects.

AB - Paranasal sinus cancers are rare diseases, accounting for about 5% of all head and neck malignancies. The variety of histological types and the overlapping pathological features with other entities constitute difficulties in pathologic interpretation, often requiring a skilled interpretation or a second opinion. Treatment of locally advanced disease relies on surgery and radiation therapy for operable disease, with a possible role for systemic treatment in selected histologies within a multimodal approach; unresectable paranasal sinus cancers are generally treated with a combination of radiotherapy and chemotherapy. The employment of high conformal radiation techniques, such as Intensity Modulated Radiation Therapy orcharged particle therapy, proton or carbon ion therapy may improve outcome and reduce late effects. Surgical treatment has evolved due to the progressive application of transnasal endoscopic techniques for naso-ethmoidal malignancies and due to innovative reconstructive techniques after resection of cancers of the maxillary sinus. Because of the rarity and complexity of this disease, multicenter trials represent an urgent need to improve prognosis and to reduce treatment-related effects.

KW - Chemotherapy

KW - Environmental causes

KW - Follow up

KW - Late sequelae

KW - Paranasal sinus cancers

KW - Prognostic factors

KW - Radiotherapy

KW - Staging-molecular alterations

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84957429012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957429012&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2015.09.009

DO - 10.1016/j.critrevonc.2015.09.009

M3 - Article

AN - SCOPUS:84957429012

VL - 98

SP - 45

EP - 61

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -